Year: 2026
Type: article
Abstract: Proteins are ultimately responsible for cellular phenotypes and are targeted by most anticancer drugs. However, beyond immunohistochemistry, proteins are not typically measured in precision oncology, meaning transcriptomics is used as a proxy. To determine how informative mRNA is for guiding personalised treatments, mRNA-protein correlations were analysed in three large pan-cancer datasets and made available in a web portal ( https://oncorr.aws.procan.org.au/ ). OnCorr can be integrated into precision medicine programs to augment transcriptomics.
Source: npj Precision Oncology
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,090
Funders: Children's Medical Research, David and Elaine Potter Foundation, European Commission, Australian Cancer Research Foundation, National Breast Cancer Foundation, Ian Potter Foundation, Cancer Institute NSW, University of Sydney, NSW Ministry of Health, Medical Research Council, National Health and Medical Research Council, Cancer Council NSW, National Cancer Institute, Medical Research Future Fund
Awards: G1298984965, G1329860882, Large-scale cancer proteomic analyses for improved prediction of drug response, patient prognosis and clinical outcome, G1877097273, G2623490211, Accelerating paediatric cancer precision medicine with mass spectrometry-based proteomics, G3689963027, G4455611482, G4469232797, individualizedPaediatricCure: Cloud-based virtual-patient models for precision paediatric oncology, G5650063088, G657689336, G7480054885, individualizedPaediatricCure: Cloud-based virtual-patient models for precision paediatric oncology, G8567975949, Improving outcomes for high-risk child and adolescent cancer: from discovery to individualised treatment within a consumer partnership
OpenAlex ID: W7128743339